North America Continuous Glucose Monitoring Market Size, Share - Growth Analysis Report and Forecast Trends 2026-2030

The North America CGM market encompasses wearable sensor systems, transmitters, and associated software that continuously measure interstitial glucose levels, primarily serving type 1 and type 2 diabetes patients. The market is supported by the region's high diabetes burden, with millions of diagnosed and undiagnosed cases across the United States and Canada, and is widely recognized as the largest regional market globally. Revenue estimates vary across industry analyses, with no government statistical agency publishing official market-size figures for this specific product category.

• •Estimated 2025 market value around $6.97 billion with an annual growth rate near 11.3%
• •North America accounts for roughly 60% or more of global CGM revenue
• •No official government data source publishes dedicated CGM market statistics

Rising diabetes prevalence across North America, fueled by obesity rates and aging populations, is expanding the addressable patient base for CGM devices. Favorable insurance coverage and reimbursement policies in the United States have lowered out-of-pocket costs, making CGM accessible to a broader population beyond traditional insulin users. Ongoing product innovation, such as longer-wearing sensors, improved accuracy, and connectivity with insulin pumps and smartphone apps, has strengthened clinician and patient confidence in the technology.

• •Expanding eligibility criteria now include type 2 diabetes on basal insulin and select prediabetes populations
• •U.S. Medicare and private insurers increasingly cover CGM for broader patient categories
• •Technological advances include extended 14- to 21-day wear sensors and integration with automated insulin delivery systems

CGMs are segmented by product type into sensors, transmitters, and receivers, with sensors generating the largest share of recurring revenue. End-user channels include hospitals, clinics, and a rapidly expanding homecare segment as patients adopt at-home monitoring. The United States dominates North American demand due to its larger diabetes population, advanced healthcare infrastructure, and more expansive reimbursement frameworks compared to Canada, where market growth is somewhat constrained by provincial coverage variability.

• •Homecare/retail is the fastest-growing distribution channel, reflecting patient preference for remote monitoring
• •The U.S. accounts for the vast majority of regional revenue, with Canada representing a smaller but expanding market
• •Sensor replacements and consumables drive recurring revenue streams for manufacturers

What are the recent trends and outlook?

The market is trending toward factory-calibrated, factory-calibrated sensors that eliminate or reduce the need for fingerstick confirmations, further simplifying user experience. Integration with digital therapeutics, telehealth platforms, and artificial intelligence-driven glucose prediction algorithms is expected to deepen over the coming years. As regulatory pathways evolve and over-the-counter CGM options emerge for non-diabetic wellness use, the total addressable market could extend significantly beyond the traditional diabetes-care population.

• •Factory-calibrated and no-calibration CGM systems are reducing user burden and accelerating adoption
• •OTC and wellness-oriented CGM products are entering the consumer health space alongside traditional medical devices
• •AI-powered predictive analytics and closed-loop insulin delivery systems are shaping next-generation product roadmaps